Recent Successes and Noteworthy Future Prospects in the Treatment of Chronic Hepatitis C
Within the last year, the landscape of therapy for genotype 1 chronic hepatitis C virus (HCV) has changed dramatically as 2 much-anticipated protease inhibitors became available for use. These agents, telaprevir and boceprevir, when used in combination with pegylated interferon and ribavirin, offer...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2012-07, Vol.55 (suppl_1), p.S16-S24 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S24 |
|---|---|
| container_issue | suppl_1 |
| container_start_page | S16 |
| container_title | Clinical infectious diseases |
| container_volume | 55 |
| creator | Fox, Alyson N. Jacobson, Ira M. |
| description | Within the last year, the landscape of therapy for genotype 1 chronic hepatitis C virus (HCV) has changed dramatically as 2 much-anticipated protease inhibitors became available for use. These agents, telaprevir and boceprevir, when used in combination with pegylated interferon and ribavirin, offer patients an improved chance of cure and the opportunity for a shorter duration of therapy. Although these medications represent a significant achievement in the battle against HCV, they do not represent the final phase in the evolution of HCV therapy. Many other direct-acting antiviral agents representing several classes, as well as agents that act via host-mediated pathways, are in development. Recent proof of concept studies demonstrating the capacity to eradicate HCV without interferon signal the potential for yet another quantum leap in the field. |
| doi_str_mv | 10.1093/cid/cis391 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1021977806</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>23249664</jstor_id><sourcerecordid>23249664</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-ffd9fe2784664e9974f0b31cc703b3a59decbe54a53b66064681be7e7cf87b553</originalsourceid><addsrcrecordid>eNpd0EFLwzAUB_AgitPpxbsS8CJCNWmapDlKcU4YKjrBW2nTV9axNjNJkX17MzoVPIQXyO898v4InVFyQ4lit7qpwnFM0T10RDmTkeCK7oc74WmUpCwdoWPnloRQmhJ-iEZxLCmPiTpCH6-gofP4rdcanAOHi67CT8bDl7F-scGT3vcW8Is1bg3aO9x02C8Azy0Uvt22mhpnC2u6RuMprAvf-Mbh7AQd1MXKwemujtH75H6eTaPZ88NjdjeLdMKUj-q6UjXEMk2ESEApmdSkZFRrSVjJCq4q0CXwpOCsFIKIRKS0BAlS16ksOWdjdDXMXVvz2YPzeds4DatV0YHpXU5JTJWUKRGBXv6jS9PbLvxuq4SKheRxUNeD0mFlZ6HO17ZpC7sJKN_mnYe88yHvgC92I_uyheqX_gQcwPkAls4b-_fO4kSFjdk3VdKFQg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1026926752</pqid></control><display><type>article</type><title>Recent Successes and Noteworthy Future Prospects in the Treatment of Chronic Hepatitis C</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Fox, Alyson N. ; Jacobson, Ira M.</creator><creatorcontrib>Fox, Alyson N. ; Jacobson, Ira M.</creatorcontrib><description>Within the last year, the landscape of therapy for genotype 1 chronic hepatitis C virus (HCV) has changed dramatically as 2 much-anticipated protease inhibitors became available for use. These agents, telaprevir and boceprevir, when used in combination with pegylated interferon and ribavirin, offer patients an improved chance of cure and the opportunity for a shorter duration of therapy. Although these medications represent a significant achievement in the battle against HCV, they do not represent the final phase in the evolution of HCV therapy. Many other direct-acting antiviral agents representing several classes, as well as agents that act via host-mediated pathways, are in development. Recent proof of concept studies demonstrating the capacity to eradicate HCV without interferon signal the potential for yet another quantum leap in the field.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/cis391</identifier><identifier>PMID: 22715209</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject><![CDATA[Antiviral Agents - pharmacology ; Antivirals ; Chronic hepatitis ; Clinical Trials as Topic ; Cyclophilins - antagonists & inhibitors ; Disease control ; Drug therapy ; Drug Therapy, Combination ; Experimentation ; Genotype & phenotype ; Genotypes ; Hepacivirus - pathogenicity ; Hepacivirus - physiology ; Hepatitis ; Hepatitis C ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - prevention & control ; Hepatitis C, Chronic - virology ; Humans ; Infections ; Interferons ; Medical treatment ; Memory interference ; MicroRNAs - antagonists & inhibitors ; Oligopeptides - pharmacology ; Proline - analogs & derivatives ; Proline - pharmacology ; Protease inhibitors ; Protease Inhibitors - pharmacology ; RNA ; Transponders ; Treatment Outcome ; Viral Nonstructural Proteins - antagonists & inhibitors ; Virology ; Virus Replication]]></subject><ispartof>Clinical infectious diseases, 2012-07, Vol.55 (suppl_1), p.S16-S24</ispartof><rights>Copyright © 2012 Oxford University Press on behalf of the Infectious Diseases Society of America</rights><rights>Copyright University of Chicago, acting through its Press Jul 15, 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-ffd9fe2784664e9974f0b31cc703b3a59decbe54a53b66064681be7e7cf87b553</citedby><cites>FETCH-LOGICAL-c439t-ffd9fe2784664e9974f0b31cc703b3a59decbe54a53b66064681be7e7cf87b553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/23249664$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/23249664$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,803,27915,27916,58008,58241</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22715209$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fox, Alyson N.</creatorcontrib><creatorcontrib>Jacobson, Ira M.</creatorcontrib><title>Recent Successes and Noteworthy Future Prospects in the Treatment of Chronic Hepatitis C</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Within the last year, the landscape of therapy for genotype 1 chronic hepatitis C virus (HCV) has changed dramatically as 2 much-anticipated protease inhibitors became available for use. These agents, telaprevir and boceprevir, when used in combination with pegylated interferon and ribavirin, offer patients an improved chance of cure and the opportunity for a shorter duration of therapy. Although these medications represent a significant achievement in the battle against HCV, they do not represent the final phase in the evolution of HCV therapy. Many other direct-acting antiviral agents representing several classes, as well as agents that act via host-mediated pathways, are in development. Recent proof of concept studies demonstrating the capacity to eradicate HCV without interferon signal the potential for yet another quantum leap in the field.</description><subject>Antiviral Agents - pharmacology</subject><subject>Antivirals</subject><subject>Chronic hepatitis</subject><subject>Clinical Trials as Topic</subject><subject>Cyclophilins - antagonists & inhibitors</subject><subject>Disease control</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Experimentation</subject><subject>Genotype & phenotype</subject><subject>Genotypes</subject><subject>Hepacivirus - pathogenicity</subject><subject>Hepacivirus - physiology</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - prevention & control</subject><subject>Hepatitis C, Chronic - virology</subject><subject>Humans</subject><subject>Infections</subject><subject>Interferons</subject><subject>Medical treatment</subject><subject>Memory interference</subject><subject>MicroRNAs - antagonists & inhibitors</subject><subject>Oligopeptides - pharmacology</subject><subject>Proline - analogs & derivatives</subject><subject>Proline - pharmacology</subject><subject>Protease inhibitors</subject><subject>Protease Inhibitors - pharmacology</subject><subject>RNA</subject><subject>Transponders</subject><subject>Treatment Outcome</subject><subject>Viral Nonstructural Proteins - antagonists & inhibitors</subject><subject>Virology</subject><subject>Virus Replication</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0EFLwzAUB_AgitPpxbsS8CJCNWmapDlKcU4YKjrBW2nTV9axNjNJkX17MzoVPIQXyO898v4InVFyQ4lit7qpwnFM0T10RDmTkeCK7oc74WmUpCwdoWPnloRQmhJ-iEZxLCmPiTpCH6-gofP4rdcanAOHi67CT8bDl7F-scGT3vcW8Is1bg3aO9x02C8Azy0Uvt22mhpnC2u6RuMprAvf-Mbh7AQd1MXKwemujtH75H6eTaPZ88NjdjeLdMKUj-q6UjXEMk2ESEApmdSkZFRrSVjJCq4q0CXwpOCsFIKIRKS0BAlS16ksOWdjdDXMXVvz2YPzeds4DatV0YHpXU5JTJWUKRGBXv6jS9PbLvxuq4SKheRxUNeD0mFlZ6HO17ZpC7sJKN_mnYe88yHvgC92I_uyheqX_gQcwPkAls4b-_fO4kSFjdk3VdKFQg</recordid><startdate>20120715</startdate><enddate>20120715</enddate><creator>Fox, Alyson N.</creator><creator>Jacobson, Ira M.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20120715</creationdate><title>Recent Successes and Noteworthy Future Prospects in the Treatment of Chronic Hepatitis C</title><author>Fox, Alyson N. ; Jacobson, Ira M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-ffd9fe2784664e9974f0b31cc703b3a59decbe54a53b66064681be7e7cf87b553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antiviral Agents - pharmacology</topic><topic>Antivirals</topic><topic>Chronic hepatitis</topic><topic>Clinical Trials as Topic</topic><topic>Cyclophilins - antagonists & inhibitors</topic><topic>Disease control</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Experimentation</topic><topic>Genotype & phenotype</topic><topic>Genotypes</topic><topic>Hepacivirus - pathogenicity</topic><topic>Hepacivirus - physiology</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - prevention & control</topic><topic>Hepatitis C, Chronic - virology</topic><topic>Humans</topic><topic>Infections</topic><topic>Interferons</topic><topic>Medical treatment</topic><topic>Memory interference</topic><topic>MicroRNAs - antagonists & inhibitors</topic><topic>Oligopeptides - pharmacology</topic><topic>Proline - analogs & derivatives</topic><topic>Proline - pharmacology</topic><topic>Protease inhibitors</topic><topic>Protease Inhibitors - pharmacology</topic><topic>RNA</topic><topic>Transponders</topic><topic>Treatment Outcome</topic><topic>Viral Nonstructural Proteins - antagonists & inhibitors</topic><topic>Virology</topic><topic>Virus Replication</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fox, Alyson N.</creatorcontrib><creatorcontrib>Jacobson, Ira M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fox, Alyson N.</au><au>Jacobson, Ira M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent Successes and Noteworthy Future Prospects in the Treatment of Chronic Hepatitis C</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2012-07-15</date><risdate>2012</risdate><volume>55</volume><issue>suppl_1</issue><spage>S16</spage><epage>S24</epage><pages>S16-S24</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Within the last year, the landscape of therapy for genotype 1 chronic hepatitis C virus (HCV) has changed dramatically as 2 much-anticipated protease inhibitors became available for use. These agents, telaprevir and boceprevir, when used in combination with pegylated interferon and ribavirin, offer patients an improved chance of cure and the opportunity for a shorter duration of therapy. Although these medications represent a significant achievement in the battle against HCV, they do not represent the final phase in the evolution of HCV therapy. Many other direct-acting antiviral agents representing several classes, as well as agents that act via host-mediated pathways, are in development. Recent proof of concept studies demonstrating the capacity to eradicate HCV without interferon signal the potential for yet another quantum leap in the field.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>22715209</pmid><doi>10.1093/cid/cis391</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2012-07, Vol.55 (suppl_1), p.S16-S24 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1021977806 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Antiviral Agents - pharmacology Antivirals Chronic hepatitis Clinical Trials as Topic Cyclophilins - antagonists & inhibitors Disease control Drug therapy Drug Therapy, Combination Experimentation Genotype & phenotype Genotypes Hepacivirus - pathogenicity Hepacivirus - physiology Hepatitis Hepatitis C Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - prevention & control Hepatitis C, Chronic - virology Humans Infections Interferons Medical treatment Memory interference MicroRNAs - antagonists & inhibitors Oligopeptides - pharmacology Proline - analogs & derivatives Proline - pharmacology Protease inhibitors Protease Inhibitors - pharmacology RNA Transponders Treatment Outcome Viral Nonstructural Proteins - antagonists & inhibitors Virology Virus Replication |
| title | Recent Successes and Noteworthy Future Prospects in the Treatment of Chronic Hepatitis C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T05%3A29%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20Successes%20and%20Noteworthy%20Future%20Prospects%20in%20the%20Treatment%20of%20Chronic%20Hepatitis%20C&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Fox,%20Alyson%20N.&rft.date=2012-07-15&rft.volume=55&rft.issue=suppl_1&rft.spage=S16&rft.epage=S24&rft.pages=S16-S24&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/cis391&rft_dat=%3Cjstor_proqu%3E23249664%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1026926752&rft_id=info:pmid/22715209&rft_jstor_id=23249664&rfr_iscdi=true |